J&J Announces Promising Phase 1b/2 Data For Amivantamab Combination In Metastatic Colorectal Cancer

5 days ago

( RTTNews ) - Janssen-Cilag International NV, a Johnson & Johnson ( JNJ ) company, announced new data from the Phase 1b/2 OrigAMI-1 study, which showed amivantamab combined with chemotherapy ( mFOLFOX6 [FOLFOX] or FOLFIRI ) demonstrated promising rapid and durable antitumour activity in patients ...

Ticker	Sentiment	Impact
JNJ	Somewhat Bullish	36 %